We are live on ! Find out more
BCTXW

BriaCell Therapeutics Corp Warrant

Delisted

BCTXW was delisted on the 26th of February, 2026.

0 hedge funds and large institutions have $0 invested in BriaCell Therapeutics Corp Warrant in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

6.27% less ownership

Funds ownership: 6.27%0% (-6.3%)

100% less funds holding

Funds holding: 70 (-7)

100% less capital invested

Capital invested by funds: $8.31K → $0 (-$8.31K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
Holders Change
-7
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
RAM
1
Redmond Asset Management
Virginia
-$2.35K -75,000 Closed
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
-$3.54K -67,111 Closed
VF
3
Virtu Financial
New York
-$1K -26,293 Closed
HF
4
HRT Financial
New York
-$1K -20,844 Closed
LGM
5
L1 Global Manager
-$370 -7,000 Closed
NFSG
6
Newbridge Financial Services Group
Florida
-$53 -1,000 Closed

BCTXW Hedge Fund Activity: Q1 2026 in Review

0 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Corp Warrant (BCTXW) for Q1 2026, worth a combined $0 — down 100% from $8.31K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of BCTXW and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Susquehanna International Group, exiting entirely with an estimated $3.54K sold.

  • 0 institutional investors held BriaCell Therapeutics Corp Warrant (BCTXW) as of Q1 2026, down from 7 in Q4 2025.
  • Funds reported $0 of BriaCell Therapeutics Corp Warrant stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new BriaCell Therapeutics Corp Warrant positions in Q1 2026 and 7 closed out, a net change of -7 holders.
  • The largest BriaCell Therapeutics Corp Warrant seller in Q1 2026 was Susquehanna International Group, an estimated $3.54K sold.

Based on aggregated 13F filings for Q1 2026.